Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Item

http://www.wikidata.org/entity/Q36443804

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@ast

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@en

type

Item

label

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@ast

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@en

prefLabel

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@ast

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

@en

P1476

Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective

@en

P2093

Andrea Stucchi

http://www.w3.org/2001/XMLSchema#string

Daniele Cusi

http://www.w3.org/2001/XMLSchema#string

Maria Antonietta Rizzo

http://www.w3.org/2001/XMLSchema#string

P2860

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Oral phosphate binders in patients with kidney failure

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial.

Uric acid and cardiovascular risk.

P304

59-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040622311433771

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario Cozzolino

Maurizio Gallieni

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23251769

http://www.w3.org/2001/XMLSchema#string

P932

3513902

http://www.w3.org/2001/XMLSchema#string